Development of diagnosis method for LTBI with circulating miRNA
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA629528 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11652707.fastq.gz | Fastqsanger.gz | |||
| SRR11652708.fastq.gz | Fastqsanger.gz | |||
| SRR11652709.fastq.gz | Fastqsanger.gz | |||
| SRR11652710.fastq.gz | Fastqsanger.gz | |||
| SRR11652711.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 32 |
Similar Datasets
Project description:When exposed to M. tuberculosis, 25-50% become infected, of which 10-20% having several symptoms. Currently, there is no marker for judging the efficacy of M tuberculosis (Mtb) treatment, and it is judged based on the appearance of subjective symptoms and radiological findings. In this study, we attempted to establish a marker to distinguish patients who relapsed after TB treatment from patients who had recurrence after TB treatment using the information of circulating miRNA expression. Thirty two patients with tuberculosis infection aged 18 years or older were enrolled. 16 patients had onset or recurrence of TB and 16 patients with latent tuberculosis infection (LTBI) with positive test for Interferon gamma release assays (IGRA) and no chest X-ray examination. Total RNA from serum in exosome-rich fraction was extracted and then miRNA expression analysis was performed using a next-generation sequencer and NGS data analyzed using miRDeep2. Using expression information of nine miRNAs, TB and LTBI could be separated with 71.8% accuracy. The odds ratio also was 6.16, and the p-value was 3.20e-02, respectively. The expression of hsa-miR-122-5p was significantly different between TB and LTBI (p <0.05). Here we established a novel method to efficiently differentiate LTBI from patients with tuberculosis infection. Since this method can be performed in a low invasive manner such as blood sampling, it is promising tool for utilizing follow-up of TB treatment.
2021-03-18 | GSE149645 | GEO
Project description:Objectives: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based biomarker classifier to assist in SCLC diagnoses. Materials and Methods: We profiled deregulated circulating cell-free miRNA in the plasma of SCLC patients. We tested selected miRs on a training cohort and created a classifier by integrating miRNA expression and patient clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Conclusion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.
2023-10-31 | GSE240757 | GEO
Project description:Objectives: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based biomarker classifier to assist in SCLC diagnoses. Materials and Methods: We profiled deregulated circulating cell-free miRNA in the plasma of SCLC patients. We tested selected miRs on a training cohort and created a classifier by integrating miRNA expression and patient clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Conclusion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.
2023-10-31 | GSE240758 | GEO
Project description:Clinical Utility of Circulating MicroRNA Signatures for Breast Cancer Diagnosis
| PRJNA179163 | ENA
Project description:Global circulating miRNA screen after morphine delivery
| PRJNA809352 | ENA
Project description:Circulating miRNA expression profiling in primary aldosteronism
| PRJNA521750 | ENA
Project description:We applied a cell population transcriptomics strategy to sorted human memory CD8 T cells to define novel immune signatures of latent tuberculosis infection (LTBI) and understand the phenotype of tuberculosis (TB)-specific T cells. We found a 41-gene signature that could discriminate between memory CD8 T cells from healthy LTBI subjects and noninfected controls. The gene signature was dominated by genes known to be associated with mucosal associated invariant T cells (MAITs) and reflected the lower frequency of MAITs observed in individuals with LTBI. There was no evidence for a conventional CD8 T cell specific signature between the two cohorts. We therefore investigated the MAITs in more detail in these cohorts. Phenotyping based on Vα7.2 and CD161 expression and MR1 tetramers revealed 2 distinct populations of CD8+Vα7.2+CD161+ T cells: MR1 tetramer+ and MR1 tetramer−, both of which had a distinct gene expression profile compared to CD8 memory T cells. Transcriptomic analysis of LTBI vs. noninfected individuals did not reveal significant differences for MR1 tetramer+ cells. However, gene expression of MR1 tetramer− cells showed a very different profile with large inter-individual diversity and a TB-specific signature. This was further strengthened by a more diverse TCR-α and -β repertoire of MR1 tetramer− cells as compared to MR1 tetramer+. Thus, cell population transcriptomics revealed a dominant MAIT signature in CD8 memory T cells that upon detailed investigation provided novel insights into the phenotype of different MAIT populations implicated in tuberculosis.
2020-05-13 | GSE132790 | GEO
Project description:Differential diagnosis of adrenocortical adenoma and carcinoma is of pivotal clinical relevance, as the prognosis and clinical management of benign and malignant adrenocortical tumours is entirely different. Circulating microRNAs are promising biomarker candidates of malignancy in several tumours. In the present study we investigate circulating microRNAs in adrenocortical tumours and to evaluate their potential applicability as biomarkers of malignancy. For the miRNA profiling, 8 preoperative plasma samples obtained from patients with adrenocortical adenomas and carcinomas and were studied by microarray.
2013-11-19 | E-GEOD-49674 | biostudies-arrayexpress
Project description:We investigated whether circulating microRNAs (miRNAs) are associated with residual insulin secretion at diagnosis and predict the severity of its future decline. We studied 53 newly diagnosed subjects enrolled in placebo groups of TrialNet clinical trials. We measured serum levels of 2,083 miRNAs using RNAseq technology, in fasting samples from the baseline visit (<100 days from diagnosis), during which residual insulin secretion was measured with a mixed meal tolerance test (MMTT). Area under the curve (AUC) C-peptide and peak C-peptide were stratified by quartiles of expression of 31 miRNAs. After adjustment for baseline C-peptide, age, BMI and sex, baseline levels of miR-3187-3p, miR-4302, and the miRNA combination of miR-3187-3p/miR-103a-3p predicted differences in MMTT C-peptide AUC/peak levels at the 12-month visit; the combination miR-3187-3p/miR-4723-5p predicted proportions of subjects above/below the 200 pmol/L clinical trial eligibility threshold at the 12-month visit. Thus, miRNA assessment at baseline identifies associations with C-peptide and stratifies subjects for future severity of C-peptide loss after 1 year. We suggest that miRNAs may be useful in predicting future C-peptide decline for improved subject stratification in clinical trials.
2020-09-01 | GSE157177 | GEO
Project description:A plasma miRNA-based classifier for small cell lung cancer diagnosis [miRNA-Seq]
| PRJNA1005200 | ENA